Latest Breaking News On - Research in multiple sclerosis - Page 3 : comparemela.com

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Long-term CNM-Au8 treatment demonstrated significant and clinically meaningful improvement of vision as measured by low contrast letter acuity (LC.

West palm beachUnited statesSalt lake cityDavid schullKevin gardnerIgnacio guerrero rosSecurities exchangeClene incResearch in multiple sclerosisClene nanomedicine incRusso partnersAmericas committee for treatmentAmericas committeeMultiple sclerosisLong term extension clinical resultsClene nanomedicine

Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

Sustained efficacy was confirmed with an annualized relapse rate of 0.098 and 67% of patients were relapse-free at six years Safety was consistent with prior findings and the established safety.

West palm beachUnited statesJennifer hadlockDamemarie paulJohn delucaBristol myers squibbBruce creeKrzysztof selmajHans peter hartungJonathan sadehDiego centonzeExchange commissionWeill institute for neurosciencesResearch in multiple sclerosisUniversity of california san franciscoUcsf ms center

EQS-News: Immunic, Inc : Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

EQS-News: Immunic, Inc : Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesEdna kaplanRobertj foxJessica breuAlexandra herrmannPaula schwartzDaniel vittMellen centerAmericas committee for treatmentResearch in multiple sclerosisNeurological instituteImmunic incExchange commissionDistribution servicesRx communications groupPresents data from phase

Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024

Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

United statesWest palm beachStephen gunnionDaniel vittAmericas committee for treatmentResearch in multiple sclerosisImmunic incAmericas committeeMultiple sclerosisEpstein barr virus

Immunic to present data for lead asset vidofludimus calcium from Phase 2 MS and COVID-19 trials

Immunic Inc (NASDAQ:IMUX) announced that it will present data from its Phase 2 CALLIPER and CALVID-1 clinical trials of its lead asset vidofludimus calcium.

West palm beachUnited statesDaniel vittImmunic incResearch in multiple sclerosisAmericas committee for treatmentAmericas committeeMultiple sclerosis